Written by: Emma Shanks, Robin Ketteler, Daniel Ebner
This article provides a comprehensive summary of the capabilities, funding sources and disease indications addressed by 24 drug discovery facilities in the UK. Strategic alliances between academia, the pharmaceutical industry and the UK government exemplify the high esteem in which drug discovery in academic and not-for-profit environments is held.
The article has been published in Nature Reviews Drug Discovery.
To read it, please go to http://www.nature.com/nrd/journal/vaop/ncurrent/full/nrd4661.html